- Healthcare Momentum: Big Pharma Deals and Approvals - Jul 16Lilly's $2.8B psychedelics buyout, Merck's first-in-class PCSK9 pill approval and upbeat biotech trial data led today's healthcare headlines. Funding and policy news add texture for you going into tomorrow.
- Healthcare: CMS, Costs and Legal Wins - Jul 16CMS signaled a possible overhaul of how clinical software and AI get paid, while a Missouri ballot raises tax risk for medical services. Legal wins for HaloMD and new public-health data add nuance for investors.
- Healthcare Momentum on Data, Approvals - Jul 15Today brought forward-looking clinical wins, an FDA approval, and fresh IPO filings that kept biotech momentum alive. You should watch launch details, regulatory politics, and upcoming data readouts.
- Healthcare Roundup - Jul 15Regulatory scrutiny of Medicare Advantage and a PBM settlement headline a mixed morning for healthcare. M&A in digital therapeutics and new drug licensing add growth cues while public health studies spotlight long-term risks.
- Healthcare Wrap-Up - Jul 14Today brought a mix of headwinds and selective wins across healthcare. HCA trimmed 2026 guidance after a $400M payer-mix hit, while biotechs raised fresh capital and new research highlighted clinical tools and risks.
- Healthcare Snapshot: FDA, AI, M&A - Jul 14Regulatory scrutiny and enforcement sit alongside fresh scientific wins and steady hospital dealmaking. Today’s briefing parses FDA criticism, new diagnostics, AI results and what could move stocks.
- Healthcare Wrap-Up Jul 13Clinical wins and stronger diagnostic data led the headlines today, with Freenome results and biotech study rebounds drawing investor attention. Policy and payer stories added caution, so stay selective as you watch upcoming catalysts.
- Healthcare: Cancer Breakthrough and Policy Risks - Jul 13A major advance in pancreatic cancer research sparks excitement while Medicaid funding fights, caregiver cuts, and rising dementia trends temper the outlook. Your guide to what matters in healthcare today.
- Healthcare Wrap-Up Jul 12Preclinical menin inhibition offers a potential oncology avenue while new menopause guidance and lifestyle research keep public-health themes in focus. Markets were closed Sunday; note developments heading into Monday.
- Healthcare Snapshot - Jul 12A mix of clinical wins, program cuts and policy moves shaped the healthcare beat over the weekend. Read what mattered and what you should watch heading into next week.
- Healthcare Wrap-Up: AI, GLP-3, Policy Jul 11AI and drug-design advances and a major GLP-3 phase 3 win dominated the headlines, but policy moves, program cuts and strikes temper the mood. Read a practical summary of implications heading into the next session.
- Healthcare Roundup - Jul 11Clinical wins and policy headwinds shape this weekend's healthcare headlines. Read how a new lung cancer result, strikes, regulatory risks, and public-health studies could affect the sector heading into next week.
- Healthcare Wrap Jul 10: Clinical Wins, Policy HeadwindsClinical breakthroughs and biotech wins competed with policy and provider stress today. Read a concise wrap of trial progress, regulatory risks, strikes, and a major legal settlement that could shape near-term healthcare moves.
- Healthcare Roundup: Key Developments - Jul 10Mixed clinical wins and policy shifts mark today’s healthcare tape. Clinical wins in neonatal care and sleep research sit alongside insurer pressures and a major Roche pipeline cut.
- Healthcare Faces Clinical Setbacks - Jul 9 WrapClinical disappointments and a corporate lawsuit set a cautious tone for healthcare on Jul 9. Research wins and new federal funding offer long-term upside, but near-term headwinds persist.
- Healthcare Faces Trial Setback, System Strain - Jul 9AstraZeneca and Ionis reported a major heart-disease trial failure this morning, while public-health strains and policy pressures add to investor uncertainty. Read what moved markets overnight and what you should watch today.
- Healthcare Sector Faces Headwinds - Jul 8Policy and cost pressures set the tone across healthcare on Jul 8, with ACA premium hikes, a major hospital nurses strike and insurer program exits. Data gaps and wearable hurdles add to the near-term uncertainty.
- Healthcare: Insurers, Gene Therapy and AI - Jul 8Insurers seek a 14% median ACA premium hike as enrollment slips, while biotechs score scientific wins and a $400M funding pact for eye gene therapy. Regulatory and access risks keep the sector mixed.
- Healthcare: Mixed Wins and Risks - Jul 7 WrapBiotech funding and an FDA approval drove positive headlines today, while cyberattacks, policy pressure and safety flags kept a lid on exuberance. Read what moved the sector, what to watch next, and how these developments could affect markets tomorrow.
- Healthcare Roundup: Jul 7 Morning BriefingToday's healthcare news mixes strong R&D advances in neurology and cardiology with sharp policy and insurance pain points. You’ll want to weigh scientific momentum against affordability and coverage risks.
- Healthcare Wrap Jul 6 - Mixed Signals for InvestorsToday’s healthcare headlines mixed strong biotech financing and an IPO filing with policy pressure on drug payments and clinical oversight concerns for GLP-1 telehealth scripts. You’ll find what moved stocks, key research takeaways, and the catalysts to watch tomorrow.
- Healthcare: Policy and AI Crossroads - Jul 6A new Medicaid work rule and a high‑stakes California governor race collide with rising AI adoption and modular construction trends. Here’s what you need to know before the open.
- Healthcare Advances in Care and Therapies - Jul 5Research out of ESMO and academic centers delivered a trifecta of positive news for healthcare: a rehab program easing long COVID brain fog, genetic prediction for glaucoma, and promising early pancreatic cancer therapy data. Heading into the holiday week, these findings reinforce demand for diagnostics, rehab services, and targeted oncology R&D.
- Healthcare Morning Briefing - Jul 5A Europe survey backing state-funded fertility care meets U.K. research on persistent childhood trauma and U.S. warnings about child drownings. Heading into the July 6 session, the news creates mixed signals for healthcare investors.
- Healthcare Roundup Jul 4Research on childhood trauma, rising child drowning concerns, VR perception studies, and coverage of healthcare costs framed the sector narrative heading into the long weekend. Read what you should watch when markets reopen.
- Healthcare Policy, Funding & Public Health - Jul 4Regulatory fights over 340B discounts and a legal loss for Elevance set a cautious tone heading into the long weekend. At the same time, a $180M biotech raise and improved health data flows offer offsetting positives.
- Healthcare Wrap: Policy, Research & Funding - Jul 3Regulatory moves on 340B, Elevance's $115M dispute with CMS, and fresh biotech funding led headlines, while new research on immune signals and heart attack risk added clinical momentum. Markets were closed heading into the long weekend.
- Healthcare Headlines - Jul 3Mixed signals hit healthcare as promising ALS research and a big IPF financing clash with renewed 340B policy fights and an insurer lawsuit. Public health outbreaks add a cautionary note heading into the long weekend.
- Healthcare Wrap: Policy, M&A, Drug Wins - Jul 2Policy moves on 340B and a high-profile Medicare tussle dominated the tape, while Roche posted a phase 3 win and a PureTech-backed startup raised $180M. Read what matters for your portfolio.
- Healthcare Mixed Signals - Jul 2Outbreaks and regulatory gaps clash with promising research and AI-enabled devices. This morning's briefing explains what you need to know, from West Nile to GLP-1s and BCG findings.
- Healthcare: Trials, M&A and Policy Hits - Jul 1Clinical progress, an $800M deal and major policy signals set a mixed tone for healthcare stocks today. Read how trial data, acquisitions and Medicare GLP-1 exposure could affect companies and your watchlist.
- Healthcare: GLP-1 Wins, Biotech Deals - Jul 1New data links GLP-1 drugs to fewer deaths and amputations, while biotech funding, acquisition activity and FDA pilot programs are moving deals and pipelines. Policymakers and payers remain key catalysts to watch.
- Healthcare Wrap: Mixed Wins and Risks - Jun 30Biotech approvals, big venture funding, and new AI tools for pharma stood out today, but a Marburg outbreak and Medicaid legal fights keep risk elevated. Read what matters for your watchlist.
- Healthcare Morning Brief - Jun 30Today’s Healthcare briefing balances lab and clinical wins with policy and enrollment headwinds. Read on for clinical trial updates, a $929M buyout, TEFCA oversight, and what you should watch.
- Healthcare Wrap: Policy, M&A & Breakthroughs - Jun 29Today brought a mixed bag for healthcare: a $929M buyout after clinical setbacks, nearly 3M fewer ACA enrollees, and fresh innovation from biodegradable sensors and lung leukemia research. Read what moved the sector and what you should watch next.
- Healthcare Mixed Signals on Access and AI - Jun 29Today’s healthcare headlines balance troubling access stories with upbeat tech and care-model developments. From uninsured gunshot discharges to AI tools reaching 100,000 clinicians, here’s what you need to know.
- Healthcare Wrap-Up Jun 28Researchers find a way to reverse chemo resistance in ovarian cancer while public-health pieces on melatonin, breastfeeding and sunscreen policy spark debate. Policy and access issues keep the picture mixed for healthcare investors.
- Healthcare Roundup: FDA, BIO Takeaways - Jun 28Regulatory momentum met policy friction over the weekend: FDA accepted a Replimune filing and Merck KGaA made an $11B move, while Medicaid hearings, China deal tensions and access issues remind you to be selective.
- Healthcare Wrap - Jun 27Biotech filings and big corporate deals drew attention heading into the long weekend, even as regulatory, legal and access issues kept risk elevated. Read what matters for your watchlist.
- Healthcare Wrap: Shortages, AI, FDA Moves - Jun 27Drug shortages and regulatory tensions dominated headlines as BIO 2026 highlighted AI and policy risks. Read how FDA filings, M&A and public health studies could affect the sector heading into the long weekend.
- Healthcare Wrap: FDA Filings, BIO Tensions - Jun 26Regulatory moves and policy debates set the tone for healthcare on Jun 26. FDA acceptance and major M&A deals shared the stage with BIO conference tensions and fresh clinical findings you should know.
- Healthcare: GLP-1 Access, Elevance Payment - Jun 26Elevance Health agreed to a $342M payment amid a CMS billing probe while GLP-1 coverage headaches and new research into rare conditions keep attention on biopharma. Patient messaging and delivery innovations add operational pressure.
- Healthcare Wrap-Up - Jun 25Research breakthroughs, a $105M oncology pact with Novartis, and AI in screening dominated headlines. Policy pressure on 340B and clinical workload growth temper optimism for healthcare stocks.
- Healthcare: Policy, AI Vaccines & Spending - Jun 25Research on immune 'peacemakers' and AI-driven broad vaccines headline a mixed morning for Healthcare. Policy moves on Medicare costs and opioid treatment, plus a $5.7T spending report, give investors plenty to watch.
- Healthcare: Research & Funding Momentum - Jun 24Venture funding, big‑pharma investments and scientific breakthroughs led healthcare headlines on Jun 24. You’ll want to track funding rounds, GLP-1 spending trends, and regulatory probes heading into tomorrow.
- Healthcare Morning Briefing - Jun 24Science advances and governance shifts compete with clinical setbacks in today’s healthcare headlines. Read what research, trial news, and leadership moves mean for your portfolio and watchlist.
- Healthcare Mixed Signals on Innovation and Risk - Jun 23Innovation and enforcement collided in healthcare today. AI-driven MRI advances and a $400M IPO competed with a Pfizer clinical setback and a broad DOJ fraud crackdown. Read what matters for you tomorrow.
- Healthcare Morning Brief - Jun 23AI diagnostic wins and new disease subtypes clash with policy headaches and a pharma dispute. Read what moved the healthcare sector overnight and what to watch today.
- Healthcare Wrap-Up - Jun 22Regulatory momentum and clinical advances drove biotech optimism today while policy fights and safety concerns kept insurers and hospitals on edge. Read a concise take on what moved the sector and what you should watch next.
- Healthcare Mixed Signals: Policy, Science - Jun 22State price caps, a major gene discovery, and a growing Ebola outbreak set a mixed agenda for healthcare investors today. You should watch policy moves, public health updates, and payer strategies.